📢Thrilled to announce that TIDE-A trial is finally out on European Urology! Thanks to all coauthors for supporting 1️⃣st trial of TKI interruption in IO combo for #mRCC. sciencedirect.com/science/articl… Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Tom Powles Brian Rini, MD OncoAlert Università Cattolica Kidney Cancer IKCC Kidney Cancer

Great FDA approval update on lifileucel by Dr. Erez Baruch at Academic Tuesday today! Nice summary slide on current treatment approach for BRAF WT melanoma MD Anderson Cancer Center Ben Fangman, MD Hima Atluri, MD Tara Davidson Ryan Denu, MD, PhD Kelsey Pan, MD, MPH Bilal Anouti @kyleconcannon4

A treat to hear from the engaging and thoughtful Andy Hahn on his approach to treating patients with localized prostate cancer! MD Anderson Cancer Center

Congratulations to my superstar friend and co-fellow Marija Sullivan, MD for receiving the LBJ second-year Hematology/Oncology Fellow of the Year award!! 🥇MD Anderson Cancer Center

Really interesting early data on treatment of advanced chromophobe RCC. Early suggestion that combination therapies may be more efficacious. At #ASCO24 led by Dr. Doshi Nazli Dizman Martin Voss Pavlos Msaouel Andy Hahn

💪 Great work by MD Anderson Cancer Center fellow Dr Michael Wotman on excellent performance of 13 (‼️) HPV type ctDNA assay for pts w/HPV+ OP cancer! Ongoing PD1 trial at MDACC w/this test for HPV+ OP cancer & another PDL1/TIGIT coming for ALL ctDNA+ HPV+ cancers to #endcancer vs HPV MRD!

I never met Dr. Waun Ki Hong, but his legacy lives on in so many wonderful mentors MD Anderson Cancer Center including Matt Campbell MD, MS ! Thank you for sharing Lauren Averett Byers, MD

So thankful for Dr. Tannir! Such a wonderful teacher, mentor, and supporter of young investigators and oncologists! MD Anderson Cancer Center

Loved attending ASCO 2024 with the greatest co-fellows of all time 🤗 MD Anderson Cancer Center Peter WT Pisters, MD

Summary slide. CML response definitions Jorge Cortes MD Fadi Haddad, MD #CML

1/5 Excited to share our @MsaouelLab clinical analysis of 135 patients with #RenalMedullaryCarcinoma treated MD Anderson Cancer Center over 20 years 👉sciencedirect.com/science/articl… #endRMC #rarecancers Kidney Cancer Chris Johnson Foundation Inc. RMC Alliance R.M.C. Inc Rare Cancer Research Foundation + Pattern.org The Renal Medullary Carcinoma Research Foundation KCCure

Of all the milestones our #RenalMedullaryCarcinoma research has achieved, this is definitely a highlight. Grateful to the many people who work tirelessly to help our patients.

I’m excited to present our work exploring whether #COVID #mRNA #vaccines could impact #immunotherapy outcomes. Big thanks to #ESMO2024 conference organizers for sponsoring my trip with a travel award and MD Anderson Cancer Center for highlighting this project!

🎊 Our Latest From #BoneMets Lab & Team, now in Cancer Research Communications – Dr. Eleonora Dondossola and Dr. Matt Campbell of GU Oncology MD Anderson Cancer Center Lead⭐️S. Maksimović Stefan Maksimović👉TKI activity & efficacy (cabo, lenva, axi) in orthotopic mouse models of bone-metastatic ccRCC, studying 1⃣

👋This is Mohammad Jad, Postdoc. Fellow & Postdoc. Association Team Leader MD Anderson Cancer Center, mentored by Matt Campbell MD, MS & Omar Alhalabi, MD 👉Applying for #InternalMedicine Residency #Match2025 🙏Dreaming of becoming a humane #oncologist through purposeful science – excited to

1/5 Excited to activate this week our fourth clinical trial designed for #RenalMedullaryCarcinoma (RMC). It will also separately enroll patients with epithelioid sarcoma, another rare but deadly cancer defined by loss of the SMARCB1 tumor suppressor: clinicaltrials.gov/study/NCT06444…

⭐️Delighted to welcome Dr. Deepak Bhamidipati to our Sarah Cannon Docs Early Phase Drug Development Unit in Nashville! 🎉 🌟 Recipient of the prestigious ASCO YIA and Merit Awards, he will be a fantastic addition to our team SCRI Oncology Partners The US Oncology Network Nashville, TN ⭐️He

Tivozanib in heavily pretreated pts w/ clear cell RCC: retrospective analysis @mdandersonnews showed ORR 7.7%, PFS 3.8mos, benefit limited to pts w/ indolent disease and prolonged prior TKI therapy Andrew Johns, MD @docmattcampbell @pavlosmsaouel @onchahn doi.org/10.1093/oncolo…

🙏Honored to receive this prestigious recognition from ASCO Conquer Cancer, the ASCO Foundation alongside brilliant colleagues! Grateful to my mentors, Matt Campbell MD, MS & Omar Alhalabi, MD, & MD Anderson Cancer Center family, for their support in rare GU cancer research throughout this journey to #EndCancer.

One of many highlights this year! Great session #GU25